SARS-CoV-2 Acute Respiratory Disease Clinical Trial
— ETOCOfficial title:
Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19
The COVID-19 pandemic is a novel medical challenge, particularly because of the systemic nature of this disease. Indeed, COVID-19 affects several organs and systems at once. The brain is affected in several ways: direct infection of nerve cells by SARS-CoV-2, inflammation of the central nervous system, severe systemic inflammation damaging nerve cells, global cerebral ischaemia related to respiratory failure, thromboembolic events related to increased intravascular coagulation and severe psychological stress. As a result, COVID-19 sometimes manifests as neurological and neuropsychiatric symptoms such as dizziness, sleep disturbances, cognitive deficits, delirium, or severe depression. Sudden loss of smell is a common symptom associated with COVID-19 and SARS-CoV-2 infection of neurons in the olfactory system has been reported in both hamsters and humans. The vast majority of COVID-19 patients recover their olfactory function within a few weeks. However, a significant minority of infected individuals (1 in 5 cases) still suffers from olfactory disorders (anosmia, hyposmia and/or parosmia) several months after the primary infection. These olfactory disorders are frequently associated with depressive behaviour and cognitive complaints. In PET scans, it is even possible to correlate this cognitive dysfunction with hypometabolism of certain brain regions, including the olfactory gyrus. This project proposes, during one year, to evaluate and follow the evolution of the olfactory capacities of patients suffering from persistent smell disorder since one year (+/- 4 months) following COVID-19. The issue is to study the link between viral persistence in the olfactory sensory organ, chronic inflammation, and central damage to the olfactory system. The follow-up of the evolution of olfactory and neurocognitive capacities, in an integrative way by means of molecular, physiological and behavioural approaches, will inform us on the specificities of "COVID-long" and on the level of peripheral and/or central damage of the olfactory system.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | November 9, 2024 |
Est. primary completion date | November 9, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Adults < 55 years - History of symptomatic COVID over 1 year +/- 4 months with a positive PCR diagnosis of SARS-CoV-2 - Olfactory complaint - Able to understand simple questionnaires in French. - Subject covered by French Social Security (except for Aide Médicale d'Etat). Exclusion Criteria: - Contraindication to nasal swabbing (for morphological reasons, haemostasis disorders, taking aspirin in the 15 days prior to swabbing or anticoagulants, contraindications to the use of a local anaesthetic such as a history of allergy to local anaesthetics or any other reasons judged by the clinical investigator) - To have been placed in the intensive care unit following COVID-19. - Known previous nasal-sinus pathology. - History of psychiatric pathology according to DSM IV criteria, ischaemic, neoplastic, inflammatory, infectious or neurodegenerative (meningitis, encephalopathy, encephalitis, stroke, neurodegenerative disease) known or suspected. - History of loss of sense of smell prior to COVID infection. - Patient affiliated to the Aide Médicale d'Etat. - Person deprived of liberty by judicial or administrative decision, or subject to legal protection. |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Lariboisière | Paris |
Lead Sponsor | Collaborator |
---|---|
Institut Pasteur | Hopital Lariboisière |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of olfactory responses by PEO recording and by calculating the TDI score of the Sniffin'stick tests. | To characterise the evolution of the olfactory capacities of patients suffering from persistent odour disorders following SARS-CoV-2 infection over the course of a year. | 24 months | |
Secondary | Measurement of olfactory perception threshold, olfactory discrimination capacity and odour identification. | Describe the olfactory performance | 24 months | |
Secondary | To characterise the persistence of SARS-CoV-2 in the olfactory epithelium. | Characterisation of the presence of SARS-CoV-2 by PCR in the olfactory mucosa. | 24 months | |
Secondary | To characterise any damage to the olfactory nerve | Mapping analysis of the olfactory nerve of COVID-19 patients by MRI tractography technique. | 24 months | |
Secondary | To identify the presence of inflammatory markers in patients. | Measurement of cellular and inflammatory markers in the olfactory mucosa. | 24 months | |
Secondary | Detection and measurement of markers of neurological disorders in the blood. | To identify the neurological damage in patients. | 24 months | |
Secondary | Measurement of patients' cognitive performance by neuropsychological assessment (standardised tests). | To identify possible cognitive abnormalities in these patients with prolonged loss of smell. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05063214 -
Muscle Evaluation of Patients Infected by the Coronavirus
|
||
Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
Completed |
NCT04998253 -
Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
|
Early Phase 1 | |
Active, not recruiting |
NCT05167227 -
Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?
|
N/A | |
Withdrawn |
NCT05393999 -
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
|
Phase 2 | |
Completed |
NCT05142553 -
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
|
Phase 2 | |
Recruiting |
NCT04929691 -
The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19
|
N/A | |
Completed |
NCT05142514 -
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
|
Phase 2 | |
Withdrawn |
NCT04894682 -
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
|
||
Completed |
NCT04845048 -
Active Pharmacovigilance Study of Adsorbed COVID-19 (Inactivated) Vaccine
|
||
Completed |
NCT05638178 -
The Corona Study of Middle Norway
|
||
Not yet recruiting |
NCT05248373 -
Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05074121 -
NAC for Attenuation of COVID-19 Symptomatology
|
Phase 2 | |
Completed |
NCT05305573 -
Assessing the Immunogenicity and Safety of a HIPRA's Candidate Booster Vaccination in Adults Fully Vaccinated With Adenovirus Vaccine Against COVID-19.
|
Phase 2 | |
Completed |
NCT05042193 -
A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19
|
||
Completed |
NCT04896866 -
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
|
N/A | |
Completed |
NCT04371471 -
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
|
||
Completed |
NCT05008562 -
How COVID-19 Effects to Muscle Mass Change ın ICU?
|
||
Completed |
NCT04954157 -
Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients
|
N/A | |
Withdrawn |
NCT04913142 -
About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.
|